JP2003528917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528917A5 JP2003528917A5 JP2001572104A JP2001572104A JP2003528917A5 JP 2003528917 A5 JP2003528917 A5 JP 2003528917A5 JP 2001572104 A JP2001572104 A JP 2001572104A JP 2001572104 A JP2001572104 A JP 2001572104A JP 2003528917 A5 JP2003528917 A5 JP 2003528917A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- quinazoline
- yloxy
- angiogenic
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004037 angiogenesis inhibitor Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- GCABIYVOJWRUBO-MRXNPFEDSA-N (2r)-1-[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinazolin-7-yl]oxy-3-pyrrolidin-1-ylpropan-2-ol Chemical compound C([C@@H](O)COC1=CC2=NC=NC(OC=3C(=C4C=C(C)NC4=CC=3)F)=C2C=C1OC)N1CCCC1 GCABIYVOJWRUBO-MRXNPFEDSA-N 0.000 description 1
- UCNZLDYJJUFVBL-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCCC1 UCNZLDYJJUFVBL-UHFFFAOYSA-N 0.000 description 1
- YAIZIOMJNQKWHW-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 YAIZIOMJNQKWHW-UHFFFAOYSA-N 0.000 description 1
- QLKYLLNKQLYUCK-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCC1CCN(C)CC1 QLKYLLNKQLYUCK-UHFFFAOYSA-N 0.000 description 1
- QIAQSHWCWZYWDB-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCCC1CCN(C)CC1 QIAQSHWCWZYWDB-UHFFFAOYSA-N 0.000 description 1
- OWHNSMAGPUBAHX-UHFFFAOYSA-N 4-[(4-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=CNC4=CC=3)F)N=CN=C2C=C1OCCCN1CCN(C)CC1 OWHNSMAGPUBAHX-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- NZMWZMBJACHTSF-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCCC1 NZMWZMBJACHTSF-UHFFFAOYSA-N 0.000 description 1
- XWOGDYNDOQKNBW-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCC1CCN(C)CC1 XWOGDYNDOQKNBW-UHFFFAOYSA-N 0.000 description 1
- WKHMXMYWJGLMDQ-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCC1CCN(C)CC1 WKHMXMYWJGLMDQ-UHFFFAOYSA-N 0.000 description 1
- UBQBLLUOQUWFBD-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCN(C)CC1 UBQBLLUOQUWFBD-UHFFFAOYSA-N 0.000 description 1
- CUXRYZZQLQTALS-UHFFFAOYSA-N 4-[(6-fluoro-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C(=CC=4NC=CC=4C=3)F)N=CN=C2C=C1OCCCN1CCCC1 CUXRYZZQLQTALS-UHFFFAOYSA-N 0.000 description 1
- VWIOUOMKJGDTHR-UHFFFAOYSA-N 6-methoxy-4-[(2-methyl-1h-indol-5-yl)oxy]-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(OC=3C=C4C=C(C)NC4=CC=3)N=CN=C2C=C1OCCCN1CCCC1 VWIOUOMKJGDTHR-UHFFFAOYSA-N 0.000 description 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical group COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008269.3A GB0008269D0 (en) | 2000-04-05 | 2000-04-05 | Combination chemotherapy |
| GB0008269.3 | 2000-04-05 | ||
| PCT/GB2001/001522 WO2001074360A1 (en) | 2000-04-05 | 2001-04-02 | Therapeutic combinations of antihypertensive and antiangiogenic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528917A JP2003528917A (ja) | 2003-09-30 |
| JP2003528917A5 true JP2003528917A5 (https=) | 2008-01-31 |
Family
ID=9889176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572104A Pending JP2003528917A (ja) | 2000-04-05 | 2001-04-02 | 抗高血圧薬および抗血管新生薬の治療的組合せ |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7829573B2 (https=) |
| EP (3) | EP1790340A3 (https=) |
| JP (1) | JP2003528917A (https=) |
| KR (2) | KR20080034523A (https=) |
| CN (1) | CN1431902A (https=) |
| AT (1) | ATE355065T1 (https=) |
| AU (2) | AU4438601A (https=) |
| BR (1) | BR0109729A (https=) |
| CA (1) | CA2401854A1 (https=) |
| CY (1) | CY1107615T1 (https=) |
| CZ (1) | CZ299410B6 (https=) |
| DE (1) | DE60126923T2 (https=) |
| DK (1) | DK1272186T3 (https=) |
| EE (1) | EE200200578A (https=) |
| ES (1) | ES2280349T3 (https=) |
| GB (1) | GB0008269D0 (https=) |
| HU (1) | HUP0300426A2 (https=) |
| IL (1) | IL151503A0 (https=) |
| IS (2) | IS2455B (https=) |
| MX (1) | MXPA02009743A (https=) |
| NO (2) | NO323467B1 (https=) |
| NZ (2) | NZ534455A (https=) |
| PL (1) | PL357605A1 (https=) |
| PT (1) | PT1272186E (https=) |
| RU (1) | RU2002129353A (https=) |
| SI (1) | SI1272186T1 (https=) |
| SK (1) | SK14302002A3 (https=) |
| WO (1) | WO2001074360A1 (https=) |
| ZA (1) | ZA200206959B (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381413B1 (en) * | 1998-04-17 | 2008-06-03 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
| CZ301689B6 (cs) | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| AU2001235804A1 (en) | 2000-03-06 | 2001-09-17 | Astrazeneca Ab | Therapy |
| ES2267748T3 (es) | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | Compuestos de quinazolina. |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| JP4608215B2 (ja) * | 2002-02-01 | 2011-01-12 | アストラゼネカ アクチボラグ | キナゾリン化合物 |
| DE60311788T2 (de) * | 2002-04-16 | 2007-11-22 | Astrazeneca Ab | Kombinationstherapie zur behandlung von krebs |
| US7358236B1 (en) | 2002-06-21 | 2008-04-15 | Oxigene, Inc. | Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| ES2534926T3 (es) * | 2002-07-19 | 2015-04-30 | Beth Israel Deaconess Medical Center | Métodos para tratar la preeclampsia |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| PT1592423E (pt) * | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
| GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| WO2004112801A2 (en) * | 2003-06-18 | 2004-12-29 | Angiogene Pharmaceuticals Limited | Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
| EP1648465B1 (en) * | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| EP1660504B1 (en) | 2003-08-29 | 2008-10-29 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
| EA009994B1 (ru) * | 2003-12-23 | 2008-06-30 | Пфайзер Инк. | Новые хинолиновые производные |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| WO2005092384A2 (en) * | 2004-03-23 | 2005-10-06 | Astrazeneca Ab | Combination therapy with azd2171 and a platinum anti-tumour agent |
| US20070142308A1 (en) * | 2005-04-06 | 2007-06-21 | Helmut Augustin | Angiogenesis-affecting compounds and methods for use thereof |
| US20070142433A1 (en) * | 2004-04-06 | 2007-06-21 | Helmut Augustin | Angiogenesis-affecting compounds and methods of use thereof |
| NZ550088A (en) | 2004-04-06 | 2009-08-28 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
| AU2005244167A1 (en) * | 2004-05-04 | 2005-11-24 | Beth Israel Deaconess Medical Center | Methods and compositions for treatment of preeclampsia |
| ES2282062T1 (es) | 2004-06-04 | 2007-10-16 | Teva Pharmaceutical Industries Ltd. | Composicion farmaceutica que contiene irbesartan. |
| US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
| SG155257A1 (en) * | 2004-09-24 | 2009-09-30 | Beth Israel Hospital | Methods of diagnosing and treating complications of pregnancy |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| MX2007006777A (es) | 2004-12-06 | 2007-08-06 | Avigen Inc | Ibudilast para tratar dolor neuropatico y sindromes asociados. |
| DE602005023216D1 (de) * | 2004-12-15 | 2010-10-07 | Beth Israel Hospital | Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen |
| AU2006213856B2 (en) | 2005-02-11 | 2011-03-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent |
| CA2600868A1 (en) * | 2005-03-09 | 2006-09-21 | Merck & Co., Inc. | Quinazolinone t-type calcium channel antagonists |
| BRPI0612397A2 (pt) * | 2005-07-06 | 2011-02-22 | Astrazeneca Ab | uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente |
| MX2008001838A (es) | 2005-08-08 | 2008-04-09 | Pfizer | Sales y polimorfos de un inhibidor de vegf-r. |
| EP1917024A2 (en) | 2005-08-12 | 2008-05-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating diseases with a vegf antagonist |
| WO2007071958A2 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
| ATE502641T1 (de) * | 2005-12-22 | 2011-04-15 | Astrazeneca Ab | Kombination aus azd2171 und pemetrexed |
| US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
| EP2066353B1 (en) * | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
| WO2008080110A1 (en) * | 2006-12-21 | 2008-07-03 | Alcon, Inc. | Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor |
| US20080181876A1 (en) * | 2007-01-30 | 2008-07-31 | Johnson Kirk W | Methods for treating acute and subchronic pain |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| CA2684938A1 (en) * | 2007-05-02 | 2008-11-13 | Tau Therapeutics Llc | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| WO2008137012A1 (en) * | 2007-05-03 | 2008-11-13 | Avigen, Inc. | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
| EP2175725A1 (en) * | 2007-07-10 | 2010-04-21 | Merck Sharp & Dohme Corp. | Quinazolinone t-type calcium channel antagonists |
| WO2010008554A2 (en) | 2008-07-14 | 2010-01-21 | The Regents Of The University Of Colorado | Methods and products for treating proliferative diseases |
| AU2011223883B2 (en) | 2010-03-01 | 2015-10-08 | Cavion, Inc. | Cancer diagnosis and imaging |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| CN103110614B (zh) * | 2013-01-18 | 2015-02-18 | 杭州雷索药业有限公司 | 舒洛地尔在制备抗血管生成类药物中的应用 |
| JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
| CN106572988B (zh) | 2014-04-08 | 2022-04-08 | 卫理公会医院 | Inos抑制性组合物及其作为乳腺癌治疗剂的用途 |
| KR102486321B1 (ko) | 2014-07-18 | 2023-01-09 | 사노피 | 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법 |
| US10265111B2 (en) | 2016-04-26 | 2019-04-23 | Medtronic Holding Company Sárl | Inflatable bone tamp with flow control and methods of use |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| WO2020028007A1 (en) * | 2018-07-31 | 2020-02-06 | Colorado State University Research Foundation | Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11484355B2 (en) | 2020-03-02 | 2022-11-01 | Medtronic Holding Company Sàrl | Inflatable bone tamp and method for use of inflatable bone tamp |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010797A1 (de) | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) * | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) * | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| EP0888310B1 (en) * | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| KR100567649B1 (ko) * | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CA2275708A1 (en) | 1996-12-23 | 1998-07-02 | Cambridge University Technical Services Limited | Diagnosis and treatment of pathological pregnancies |
| WO1999010349A1 (en) * | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| DE69939374D1 (de) * | 1998-03-17 | 2008-10-02 | Genentech Inc | Zu vegf und bmp1 homologe polypeptide |
| US6191144B1 (en) * | 1998-08-17 | 2001-02-20 | Warner-Lambert Company | Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis |
| ES2216630T3 (es) | 1998-09-09 | 2004-10-16 | Scios Inc | Metodos de tratar la hipertension dependiente de la sal. |
| DE60032459D1 (de) * | 1999-01-15 | 2007-02-01 | Medstar Res Inst | Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1 |
| SK288365B6 (sk) * | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| CZ301689B6 (cs) * | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| MXPA03000388A (es) * | 2000-07-13 | 2003-09-25 | Alteon Inc | Metodo para tratar enfermedades fibroticas u otras indicaciones ic. |
| GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| KR20050056190A (ko) | 2002-08-09 | 2005-06-14 | 아스트라제네카 아베 | 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료 |
| GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| PT1592423E (pt) | 2003-02-13 | 2011-06-16 | Astrazeneca Ab | Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 |
| GB0310401D0 (en) | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| EP1648465B1 (en) | 2003-07-10 | 2010-08-25 | AstraZeneca AB | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0316123D0 (en) | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0316127D0 (en) | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0406446D0 (en) | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0406445D0 (en) | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| WO2005092384A2 (en) | 2004-03-23 | 2005-10-06 | Astrazeneca Ab | Combination therapy with azd2171 and a platinum anti-tumour agent |
| WO2006035203A1 (en) | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Cancer combination therapy comprising azd2171 and imatinib |
| KR20070072543A (ko) | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| BRPI0612397A2 (pt) | 2005-07-06 | 2011-02-22 | Astrazeneca Ab | uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente |
| CA2633211A1 (en) | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| WO2007071958A2 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
| ATE502641T1 (de) | 2005-12-22 | 2011-04-15 | Astrazeneca Ab | Kombination aus azd2171 und pemetrexed |
| EP2066353B1 (en) | 2006-09-29 | 2013-01-02 | AstraZeneca AB | Combination of zd6474 and bevacizumab for cancer therapy |
| US20100130519A1 (en) | 2007-04-13 | 2010-05-27 | Stephen Robert Wedge | Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii |
-
2000
- 2000-04-05 GB GBGB0008269.3A patent/GB0008269D0/en not_active Ceased
-
2001
- 2001-04-02 RU RU2002129353/14A patent/RU2002129353A/ru unknown
- 2001-04-02 CA CA002401854A patent/CA2401854A1/en not_active Abandoned
- 2001-04-02 AU AU4438601A patent/AU4438601A/xx active Pending
- 2001-04-02 EP EP07003863A patent/EP1790340A3/en not_active Withdrawn
- 2001-04-02 AT AT01917305T patent/ATE355065T1/de active
- 2001-04-02 PL PL01357605A patent/PL357605A1/xx not_active Application Discontinuation
- 2001-04-02 KR KR1020087007835A patent/KR20080034523A/ko not_active Ceased
- 2001-04-02 MX MXPA02009743A patent/MXPA02009743A/es active IP Right Grant
- 2001-04-02 SK SK1430-2002A patent/SK14302002A3/sk unknown
- 2001-04-02 PT PT01917305T patent/PT1272186E/pt unknown
- 2001-04-02 DK DK01917305T patent/DK1272186T3/da active
- 2001-04-02 HU HU0300426A patent/HUP0300426A2/hu unknown
- 2001-04-02 CZ CZ20023304A patent/CZ299410B6/cs not_active IP Right Cessation
- 2001-04-02 EP EP01917305A patent/EP1272186B1/en not_active Expired - Lifetime
- 2001-04-02 CN CN01807430A patent/CN1431902A/zh active Pending
- 2001-04-02 US US10/240,413 patent/US7829573B2/en not_active Expired - Fee Related
- 2001-04-02 DE DE60126923T patent/DE60126923T2/de not_active Expired - Lifetime
- 2001-04-02 JP JP2001572104A patent/JP2003528917A/ja active Pending
- 2001-04-02 NZ NZ534455A patent/NZ534455A/en unknown
- 2001-04-02 SI SI200130715T patent/SI1272186T1/sl unknown
- 2001-04-02 KR KR1020027013170A patent/KR100849149B1/ko not_active Expired - Fee Related
- 2001-04-02 NZ NZ520938A patent/NZ520938A/en unknown
- 2001-04-02 EE EEP200200578A patent/EE200200578A/xx unknown
- 2001-04-02 BR BR0109729-6A patent/BR0109729A/pt not_active Application Discontinuation
- 2001-04-02 ES ES01917305T patent/ES2280349T3/es not_active Expired - Lifetime
- 2001-04-02 EP EP06003576A patent/EP1658849A3/en not_active Withdrawn
- 2001-04-02 IL IL15150301A patent/IL151503A0/xx unknown
- 2001-04-02 WO PCT/GB2001/001522 patent/WO2001074360A1/en not_active Ceased
- 2001-04-02 AU AU2001244386A patent/AU2001244386B2/en not_active Ceased
-
2002
- 2002-08-29 ZA ZA200206959A patent/ZA200206959B/en unknown
- 2002-09-20 IS IS6557A patent/IS2455B/is unknown
- 2002-10-04 NO NO20024814A patent/NO323467B1/no not_active IP Right Cessation
-
2006
- 2006-05-08 NO NO20062050A patent/NO326277B1/no not_active IP Right Cessation
-
2007
- 2007-04-17 CY CY20071100523T patent/CY1107615T1/el unknown
-
2008
- 2008-04-16 IS IS8726A patent/IS8726A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528917A5 (https=) | ||
| RU2002129353A (ru) | Терапевтические сочетания гипотензивного и антиангиогенного лекарственных средств | |
| RU2407532C9 (ru) | Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток | |
| RU2018120330A (ru) | Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения | |
| US20100173954A1 (en) | Treatment of cancers having resistance to chemotherapeutic agents | |
| RU2357734C2 (ru) | КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ | |
| US20120157472A1 (en) | Method for treating colorectal cancer | |
| JP2005502643A5 (https=) | ||
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| JP2015526410A5 (https=) | ||
| JP2016538313A5 (https=) | ||
| JP2004536066A5 (https=) | ||
| JP5948246B2 (ja) | Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法 | |
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| CA3241001A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer | |
| JP2009532438A5 (https=) | ||
| JP2006525304A (ja) | Ｓｒｃ阻害剤と組み合わせた抗血管新生剤を含む治療剤、およびその治療用用途 | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| RU2350618C2 (ru) | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ | |
| US7879868B2 (en) | Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents | |
| JPWO2021177721A5 (https=) | ||
| RU2015124954A (ru) | Фармацевтические комбинации | |
| WO2007059155A1 (en) | Treatment of cancers having resistance to chemotherapeutic agents | |
| US20160346292A1 (en) | Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor | |
| NZ535611A (en) | Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist |